Objective: Establish the proportion of adult patients with multiple failures to antiretroviral therapy regimens who could benefit from the use of R5 antagonists by determining HIV-1 tropism. Methodology: Records of 42 HIV-1-positive adult patients treated at the "Dr. Carlos Rodolfo Mejía Villatoro" of the Roosevelt Hospital, who were instructed to perform a viral tropism test of the V3 hypervariable region of glycoprotein 120 by sequencing on the MiniSeq™ - Illumina system, using the DeepChek® v2.0 software, during the period from January 2018 to February 2021. Results: Of the 42 included records of patients for whom viral tropism testing was indicated, 50.0% were male. The median age at the time of the test request was 41 years (IQR 33.3, 45.8). 61.9% corresponded to co-receptor R5. Conclusion: The high proportion of R5 virus obtained by determining HIV-1 tropism in adult patients with multiple failures is similar to that reported in other studies. The performance of this test is necessary for a targeted and personalized treatment in which patients could benefit from the use of R5 antagonists.